Trump announces trade deal with EU following months of negotiations
Compass Pathways Plc (NASDAQ:CMPS) stock has reached a new 52-week low, touching down at $2.87, marking a 73% decline from its 52-week high of $10.31. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 5.92, indicating robust short-term financial stability. This latest price point marks a significant downturn for the company, which specializes in mental health care innovations, including the development of psilocybin therapy for treatment-resistant depression. Over the past year, Compass Pathways has seen its stock value decrease sharply, with a 1-year change showing a decline of -69.63%. This substantial drop reflects investor concerns and market conditions that have weighed heavily on the company’s financial performance and outlook. Despite the decline, analysts maintain optimistic price targets ranging from $11 to $45, suggesting potential upside. For deeper insights into CMPS’s valuation and 8 additional key ProTips, access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Compass Therapeutics reported progress in its pipeline despite missing Q4 earnings estimates. The company posted a Q4 adjusted loss per share of -$0.11, slightly below analyst predictions of -$0.10, and reported no revenue for the quarter. For the full year 2024, Compass Therapeutics recorded a net loss of $49.4 million or -$0.36 per share, compared to a loss of $42.5 million or -$0.33 per share in 2023. The company highlighted its lead candidate, tovecimig, which is on track for a key data readout by the end of Q1 2025, with top-line Phase 2/3 results expected from the COMPANION-002 trial for biliary tract cancer patients. Meanwhile, Compass Pathways received a reiteration of an Overweight rating from Cantor Fitzgerald, focusing on the commercial potential of its psilocybin therapy, known as "360." Analysts noted the importance of new billing codes that enhance reimbursement processes, aiding the company’s commercialization efforts. Additionally, H.C. Wainwright maintained a Buy rating and a $45 price target on Compass Pathways, citing the potential of its investigational therapy COMP360™ for treatment-resistant depression. The firm emphasized the therapy’s rapid efficacy and scalability, alongside plans to expand research into PTSD and anorexia nervosa.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.